Characteristics and outcomes of patients with COVID-19 supported by extracorporeal membrane oxygenation: A retrospective multicenter study

Check for updates

Omar Saeed, MD,[a] Antone J. Tatooles, MD,[b,c] Muhammad Farooq, MD,[a] Gary Schwartz, MD,[d] Duc T. Pham, MD,[e] Asif K. Mustafa, MD, PhD,[b,c] David D'Alessandro, MD,[f] Sunil Abrol, MD,[g] Ulrich P. Jorde, MD,[a] Igor D. Gregoric, MD,[h] Rajko Radovancevic, MD,[h] Brian Lima, MD,[i] Benjamin S. Bryner, MD, MS,[j] Ashwin Ravichandran, MD,[k] Christopher T. Salerno, MD,[k] Philip Spencer, MD,[l] Patricia Friedmann, MS,[m] Scott Silvestry, MD,[n] and Daniel J. Goldstein, MD,[o] the COVID-19 ECMO Working Group

ADULT

ABSTRACT

Objective: To determine characteristics, outcomes, and clinical factors associated with death in patients with COVID-19 requiring extracorporeal membrane oxygenation (ECMO) support.

Methods: A multicenter, retrospective cohort study was conducted. The cohort consisted of adult patients (18 years of age and older) requiring ECMO in the period from March 1, 2020, to September 30, 2020. The primary outcome was in-hospital mortality after ECMO initiation assessed with a time to event analysis at 90 days. Multivariable Cox proportional regression was used to determine factors associated with in-hospital mortality.

Results: Overall, 292 patients from 17 centers comprised the study cohort. Patients were 49 (interquartile range, 39-57) years old and 81 (28%) were female. At the end of the follow-up period, 19 (6%) patients were still receiving ECMO, 25 (9%) were discontinued from ECMO but remained hospitalized, 135 (46%) were discharged or transferred alive, and 113 (39%) died during the hospitalization. The cumulative in-hospital mortality at 90 days was 42% (95% confidence interval [CI], 36%-47%). Factors associated with in-hospital mortality were age (adjusted hazard ratio [aHR], 1.31; 95% CI, 1.06-1.61 per 10 years), renal dysfunction measured according to serum creatinine level (aHR, 1.21; 95% CI, 1.01-1.45), and cardiopulmonary resuscitation before ECMO placement (aHR, 1.87; 95% CI, 1.01-3.46).

Conclusions: In patients with severe COVID-19 necessitating ECMO support, in-hospital mortality occurred in fewer than half of the cases. ECMO might serve as a viable modality for terminally ill patients with refractory COVID-19. (J Thorac Cardiovasc Surg 2022;163:2107-16)

90-day cumulative incidence: 42%, 95% CI: 36-47%

Number at risk 292 225 125 59 36

More than half of the patients survived after ECMO support for COVID-19.

CENTRAL MESSAGE

ECMO can be a suitable method of mechanical support for patients with refractory respiratory failure from COVID-19.

PERSPECTIVE

In this retrospective multicenter study, the cumulative incidence of in-hospital mortality for patients with COVID-19 who received ECMO was 42%. Older age, renal dysfunction, and cardiopulmonary resuscitation before ECMO placement were associated with death during hospitalization.

Abbreviations and Acronyms
aHR = adjusted hazard ratio
ARDS = acute respiratory distress syndrome
CI = confidence interval
ECMO = extracorporeal membrane oxygenation
ELSO = Extracorporeal Life Support Organization
FiO2 = fraction of inspired oxygen
IQR = interquartile range
PaO2 = partial pressure of oxygen
VA = venoarterial
VV = venovenous

Scanning this QR code will take you to the table of contents to access supplementary information.

VIDEO 1. Oral slide presentation of the study given by the lead author, Dr Omar Saeed. Video available at: https://www.jtcvs.org/article/S0022-5223(21)00801-1/fulltext.

Mortality with COVID-19 is related to progressive respiratory failure leading to acute respiratory distress syndrome (ARDS) with eventual cardiopulmonary collapse.[1-3] Institution of mechanical ventilation support in these patients during the early pandemic period was associated with a disturbingly high mortality nearing 90%.[2] Although extracorporeal membrane oxygenation (ECMO) has been used during ARDS in non-COVID-19 patients with variable success,[4] its role remains undetermined in those afflicted with severe respiratory failure from COVID-19. Although ECMO can often lead to normalization of gas exchange and acid-base status and it might provide time for resolution of the pulmonary insult, its use is associated with major complications including bleeding, thrombosis, infection, and stroke, which collectively occur in most cases.[5] Moreover, ECMO is highly resource-intensive and most implanting centers can only offer such mechanical support to a limited number of patients.

In the early COVID-19 experience in 2020, scant reports and single-center series of outcomes with ECMO showed variability in mortality ranging from 25% to 90%.[6-11] Despite the absence of rigorous and adjusted outcomes data, ECMO was suggested for appropriate patients with COVID-19 and was commonly used by experienced centers in the United States.[12,13] For optimal usage of this limited yet potentially life-saving modality, we sought to determine the characteristics, outcomes, and clinical factors associated with death during hospitalization in patients with COVID-19 supported with ECMO (Video 1).

METHODS
Study Population
Our study was a multicenter, retrospective cohort study of patients aged 18 years and older, with COVID-19 confirmed with a positive real-time reverse transcriptase polymerase chain reaction assay, who received ECMO support anytime between March 1, 2020, and September 30, 2020 (Figure 1). Investigators at the data coordination site at Montefiore Medical Center invited centers for participation by directly contacting surgical directors of mechanical circulatory programs. A data use agreement was mutually agreed upon between every participating center and the data coordinating institution at Montefiore Medical Center, Albert Einstein College of Medicine. The study was approved by the institutional review board at all the participating centers and informed consent was waived. Institutional review board approval was granted on April 5, 2020, under protocol number 2020-11375.

Data Source
A data capture tool was created using Research Electronic Data Capture for record entry by the participating centers. Data fields included demographic characteristics, laboratory parameters, ECMO characteristics, and patient outcomes. All data were anonymized. Before data entry, sites were individually familiarized with the data capture tool and consistency was ensured by continuous technical support provided by the corresponding author at the data coordination center throughout the data collection period. To maintain accuracy, the data capture fields contained checks for validity such as input masks and range rules for date fields and branching logic. Data consistency was maintained through built-in drop boxes with standardized responses. Records were manually inspected for data entry errors, such as those in date temporality, by the data coordination center and rectified by sites before analysis. All of the captured data fields are listed in Table E1.

Outcomes
The primary outcome was in-hospital mortality after ECMO placement assessed with a time to event analysis at 90 days. We used competing risk analysis to calculate the cumulative incidence of in-hospital mortality.[14] Discharge to home and transfer to a rehabilitation facility were treated as competing events. Cases transferred to another heath care facility or other inpatient settings were censored at the time of transfer. Patients who remained hospitalized at the ECMO center as of the data update through September 30, 2020, were censored with their final status as still receiving ECMO or discontinued ECMO but still hospitalized. Cumulative incidence was administratively censored at 90 days after ECMO placement. Additional outcomes that were reported include the proportion of patients with secondary infections that occurred after ECMO placement, deep venous thrombosis, stroke, limb ischemia, changes in ECMO configuration, circuit exchange, and renal failure requiring dialysis. Causes of death during hospitalization were also reported.

Study Question: What is the 90-day outcome of Patients with COVID-19 Supported by Extracorporeal Membrane Oxygenation?

Methods: A retrospective cohort study of 292 patients from 17 centers in the United States

Results: The cumulative in-hospital mortality at 90-days was 42% (95% CI: 36-47%)

90-day cumulative incidence: 42%, 95% CI: 36-47%

Number at risk   292   225   125   59   36

Implications: ECMO can be a viable method of mechanical support for patients with refractory respiratory failure from COVID-19

FIGURE 1. A multicenter, retrospective cohort study of 292 patients with COVID-19 given extracorporeal membrane oxygenation (ECMO) in 17 centers across the United States from March 1, 2020, to September 30, 2020. Clinical characteristics and outcomes were entered into a Research Electronic Data Capture (REDCap) database. The primary outcome of cumulative in-hospital mortality at 90 days was 42% (95% confidence interval [CI], 36%-47%).

Statistical Analysis

Continuous data are displayed as mean ± SD or median quartile 1-quartile 3 interquartile range (IQR) and categorical data are shown as proportions. Comparisons between survival curves are on the basis of Fine and Gray's method.[15] A multivariable Cox regression analysis using Fine and Gray's subdistribution model to accommodate competing risks was used to determine factors associated with in-hospital mortality. Variables included in the model were those known to have an association with mortality during COVID-19 on the basis of existing literature, captured for >80% of cases or with a univariate association with mortality at a $P < .2$. The model included the following variables: age, sex, body mass index, race/ethnicity, presence of comorbidities, being transferred from another center, cardiopulmonary resuscitation before ECMO, usage of vasopressors, PaO2 to FiO2 ratio, serum creatinine and lactate dehydrogenase levels before ECMO, time from intubation to ECMO, and intravenous steroid use. Presence of comorbidities was treated as a single binary variable and was marked as yes if the patient had either a history of hypertension and/or diabetes mellitus. A supplemental model was made in which hypertension and diabetes mellitus were present as separate covariates (Figure E1). The number of observations for each covariate are listed in Table E2. Because lactate dehydrogenase was missing in >10% of the patients, we created a categorical variable using tertile cut points with an additional category for missing values and added this variable to the multivariable model. No data were imputed and the Cox multivariable model contained 255 (87%) of the possible 292 cases. Stata version 16 (Stata Corp, LLC, College Station, Tex) and SAS software version 9.4 (SAS Institute Inc, Cary, NC) was used for all statistical analyses.

RESULTS

Patient Characteristics

Overall, 292 patients with COVID-19 from 17 centers (Figure 2) were supported by ECMO during the study period and comprised the study cohort. They were 49 (IQR, 39-57) years old, 81 (28%) were female, and 131 (45%) were classified as Hispanic. Within the entire cohort, 179 (62%) had preexisting comorbidities, including 119 (41%) with hypertension and 90 (31%) with diabetes mellitus. One hundred sixty-four (56%) were transferred from another center for ECMO placement and 34 (12%) were given ECMO after having received cardiopulmonary resuscitation previously during admission. Patients presented 6 (IQR, 4-8) days after symptom onset and were given ECMO 3 (IQR, 1-6) days after intubation. Inflammatory markers including ferritin (1187; IQR, 638-1905 ng/mL), C-reactive protein (21; IQR, 9-45 mg/dL), d-dimer (8.6; IQR, 2.6-963 μg/mL), and lactate dehydrogenase (593; IQR, 429-844 U/L) levels were elevated before ECMO placement.

By the end of the follow-up period, 113 (39%) had died in the hospital, 135 (46%) were discharged or transferred alive, 19 (6%) continued with ECMO, and 25 (9%) discontinued ECMO but remained hospitalized (Figure 3). Table 1 shows a comparison of the differences in baseline demographic characteristics and laboratory parameters of patients who had died and those who were discharge or transferred, continued with ECMO and/or were hospitalized by the end of the follow-up period. Most notably, patients who died were older compared with those who were discharged or transferred alive (52 [IQR, 43-59] vs 44 [IQR, 34-54] years; $P < .01$).

ECMO Characteristics and Course

Venovenous (VV) was the predominant type of initial ECMO support provided to 280 (96%) patients, whereas venoarterial (VA) was used in 10 (3%) and 2 (1%) received VA venous. Most of the patients with VV ECMO (129; 47%) underwent dual cannulation in the femoral and jugular

FIGURE 2. Number of reported COVID-19 patients given extracorporeal membrane oxygenation by the 17 participating centers stratified according to region in the United States.

veins, whereas only 54 (19%) were cannulated in the bilateral femoral veins. Cannulas with dual lumens placed only in the internal jugular vein were used in the remainder of patients with VV ECMO as noted in Table 2. The most common location in the hospital for cannulation was at bedside or in the intensive care unit procedure room (186; 66%), followed by the operating room (74; 27%). Heparin was used for anticoagulation in 198 (71%), argatroban in 87 (32%), and bivalirudin in 28 (10%) cases. Changes in ECMO configuration (from VV to VA or from VA to VA venous) were infrequent, occurring in 19 (7%) of the patients.

Patients discharged or transferred alive received ECMO nearly 4 days earlier from the time of admission compared

with those who died (Figure 4). However, the duration of ECMO support was longer in patients who died compared with those discharged or transferred alive (19 [IQR, 9-37] vs 15 [IQR, 9-25] days; $P < .01$). Secondary infections were common during ECMO support and occurred in more than half of the patients (55%). Of these infections, bacteremia (92; 32%) and bacterial pneumonia (91; 31%) occurred most often, followed by urinary tract infections (31; 11%). Neither location of cannulation ($P = .35$) nor whether a patient was transferred ($P = .35$) were associated with bacteremia. Deep venous thrombosis was noted in 42 (15%) of the patients. Hemorrhagic stroke occurred in 17 (6%) and ischemic stroke was noted in 4 (1%) of the

FIGURE 3. Consort diagram showing the study population and their clinical outcomes. *Discharge/transfer location not available for 6 patients. *ECMO,* Extracorporeal membrane oxygenation.

TABLE 1. Baseline characteristics before ECMO placement

|	All patients (N = 292)	Still receiving ECMO (n = 19)	No ECMO but remain hospitalized (n = 25)	Discharged or transferred alive (n = 135)	Deceased (n = 113)
Age, years	49 (39-57)	51 (44-57)	49 (41-59)	44 (34-54)	52 (43-59)*
Sex, n (%)					
Female	81 (28)	1 (5)	4 (16)	42 (31)	34 (30)
Male	211 (72)	18 (95)	21 (84)	93 (69)	79 (70)
BMI	32 (29-37)	30 (25-36)	32 (27-38)	33 (30-39)	32 (29-36)
Race/ethnicity, n (%)					
Asian	11 (4)	1 (5)	2 (8)	4 (3)	4 (4)
Hispanic	131 (45)	14 (74)	9 (36)	56 (42)	52 (46)
Non-Hispanic black	59 (20)	3 (16)	5 (20)	28 (21)	23 (20)
Non-Hispanic white	66 (23)	0 (0)	9 (36)	35 (26)	22 (19)
Other/unknown	25 (8)	1 (5)	0 (0)	12 (9)	12 (11)
Preexisting comorbidities, n (%)	179 (62)	9 (50)	14 (56)	81 (60)	75 (67)
Hypertension	119 (41)	8 (42)	9 (36)	53 (39)	49 (43)
Diabetes mellitus	90 (31)	2 (16)	8 (32)	49 (36)	30 (27)
Chronic respiratory disease	8 (3)	0 (0)	2 (8)	5 (4)	2 (2)
Malignant neoplasm	4 (1)	0 (0)	1 (4)	1 (1)	2 (2)
Coronary artery disease	12 (4)	0 (0)	1 (5)	5 (4)	5 (4)
CPR before ECMO, n (%)	34 (12)	2 (11)	1 (4)	8 (6)	16 (14)
Transferred to ECMO hospital, n (%)	164 (56)	14 (74)	10 (40)	77 (57)	63 (56)
Prone positioning, n (%)	220 (77)	16 (84)	18 (72)	94 (73)	91 (81)
Time from symptom onset to admission, days	6 (4-8)	7 (6-10)	6 (4-7)	6 (4-8)	6 (3-8)
Time from admission to intubation, days	2 (1-7)	6 (0-10)	3 (0-9)	1 (1-5)	4 (1-10)*
Time from intubation to ECMO, days	3 (1-6)	4 (1-8)	2 (0-5)	3 (1-5)	4 (1-6)
Systolic blood pressure, mm Hg	111 (100-125)	116 (99-125)	113 (109-120)	116 (101-130)	106 (98-122)
Diastolic blood pressure, mm Hg	62 (55-71)	63 (55-72)	65 (56-75)	62 (55-70)	61 (54-70)
Vasopressors, %	176 (64)	6 (43)	17 (68)	75 (58)	78 (73)*
Blood gas parameters					
pH	7.31 (7.21-7.38)	7.25 (7.21-7.36)	7.33 (7.27-7.40)	7.32 (7.22-7.38)	7.29 (7.18-7.37)
PaO2/FiO2	77 (63-101)	64 (55-80)	77 (57-114)	76 (64-117)	80 (66-95)
PaCO2, mm Hg	56 (45-71)	65 (58-78)	56 (38-68)	55 (44-69)	56 (45-72)
Laboratory parameters					
White blood cells, $\times 10^3/\mu L$	14 (10-19)	17 (12-22)	12 (10-22)	12 (9-17)	14 (12-20)
Platelet count, $\times 10^3/\mu L$	252 (184-341)	323 (211-369)	188 (164-278)	262 (184-343)	248 (191-324)
Lactic acid, mmol/L	1.7 (1.3-2.5)	1.5 (1.1-2.1)	2 (1.6-2.8)	1.7 (1.1-2.2)	1.7 (1.3-2.6)
Creatinine, mg/dL	0.9 (0.7-1.4)	0.7 (0.6-1.2)	0.8 (0.7-1.3)	0.9 (0.7-1.4)	1.0 (0.7-2.0)*
International normalized ratio	1.2 (1.1-1.3)	1.1 (1.1-1.3)	1.2 (1.1-1.3)	1.2 (1.1-1.3)	1.2 (1.1-1.3)
Total bilirubin, mg/dL	0.6 (0.4-0.9)	0.5 (0.3-1.3)	0.5 (0.4-0.6)	0.6 (0.4-1.0)	0.6 (0.4-0.8)
Ferritin, ng/mL	1187 (638-1905)	1398 (858-2775)	1089 (692-1809)	1131 (517-1822)	1255 (745-1968)
C-reactive protein, mg/dL	21 (9-45)	14 (2-78)	16 (8-24)	22 (9-39)	24 (9-89)*
D-Dimer, $\mu g/mL$	8.6 (2.6-963)	7.2 (3.8-575)	20 (3.4-7424)	5.1 (2.0-762)	9.9 (3.2-1093)
Fibrinogen, mg/dL	640 (487-789)	715 (637-885)	587 (417-699)	663 (514-793)	614 (457-779)
Lactate dehydrogenase, U/L	593 (429-844)	510 (427-722)	688 (572-972)	556 (421-779)	624 (429-913)*
Procalcitonin, ng/mL	0.70 (0.3-1.9)	0.4 (0.3-0.9)	0.90 (0.3-2.2)	0.6 (0.30-1.60)	0.70 (0.3-2.1)

Number observations for each variable are listed in Table E2. Percentages represent the proportion of reported observations. Continuous variables are displayed as median (quartile 1-quartile 3). *ECMO*, Extracorporeal membrane oxygenation; *BMI*, body mass index; *CPR*, cardiopulmonary resuscitation; *PaO2/FiO2*, partial pressure of oxygen/fraction of inspired oxygen; *PaCO2*, partial pressure of carbon dioxide. *$P < .05$. Blood gas parameters were measured before ECMO placement.

ADULT

ADULT

TABLE 2. ECMO characteristics and outcomes (all patients, N = 292)

	Value
Type of initial ECMO support, n (%)	
Venovenous	280 (96)
Femoral vein–femoral vein	54 (19)
Femoral vein–right internal jugular vein	129 (47)
Femoral vein–left internal jugular vein	4 (1)
Protek Duo	59 (21)
Single right internal jugular vein	31 (11)
Venoarterial	10 (3)
Venoarterial venous	2 (1)
Hospital location for ECMO initiation, n (%)	
Bedside or ICU procedure room	186 (66)
Operating room	74 (27)
Other	16 (6)
Intravenous anticoagulation, n (%)	
Heparin	198 (71)
Bivalirudin	28 (10)
Argatroban	87 (32)
Complications, n (%)	
Secondary infection	153 (55)
Bacterial pneumonia	91 (31)
Bacteremia	92 (32)
Central line infection	8 (3)
Urinary tract infection	31 (11)
Deep vein thrombosis	42 (15)
Hemorrhagic stroke	17 (6)
Ischemic stroke	4 (1)
Limb ischemia	7 (3)
Bleeding requiring transfusion	145 (74)
Change in ECMO configuration	19 (7)
Circuit exchange	26 (13)
Renal replacement therapy	93 (46)
Died during ECMO	79 (27)
Cause of death, n (%)	
Cardiac failure	18 (16)
Hemorrhagic shock	3 (3)
Liver failure	1 (1)
Multiorgan failure	39 (34)
Respiratory failure	15 (13)
Septic shock	9 (8)
Stroke	11 (10)
Other	17 (16)
Discharge location, n (%)	
Home	55 (43)
Rehabilitation facility	54 (42)
Other health care facility	20 (15)

The Protek Duo is from TandemLife (Pittsburgh, Pa). Number of observations reported when missing values: venovenous type, 289; hospital location for ECMO cannulation, 284; heparin, 280; bivalirudin, 273; argatroban, 273; deep vein thrombosis, 278; bleeding requiring transfusion, 197; change in ECMO configuration, 276; circuit exchange, 193; renal replacement therapy, 183; discharge location, 286. Percentages represent the proportion of reported observation. *ECMO*, Extracorporeal membrane oxygenation; *ICU*, intensive care unit.

patients. After ECMO decannulation, patients remained in the hospital for 17 (IQR, 11-25) days before discharge or transfer.

A broad spectrum of adjunctive COVID-19 medical therapies were used during ECMO support as shown in Table E3. None of the reported medical therapies were associated with reduced in-hospital mortality, including intravenous steroids and remdesivir (Figure E2).

Outcomes

The cumulative incidence of in-hospital mortality at 90 days after ECMO initiation was 42% (95% confidence interval [CI], 36%-47%; Figure 5). This incidence of in-hospital death remained similar at 42% (95% CI, 35%-49%; Figure E3) after exclusion of 52 patients from centers overlapping with the recently published report from the Extracorporeal Life Support Organization (ELSO) registry.[16] Within the subset of 248 (85%) patients who died or were discharged or transferred alive, in-hospital mortality occurred in 114 (46%) of cases. The most common causes of death were multiorgan failure (39; 34%), cardiac failure (18; 16%), and respiratory failure (15; 13%). For patients who were discharged or transferred alive, post-hospital disposition was reported in all but 6 cases with 55 (43%) discharged to home, 54 (42%) transported to a rehabilitation facility, and 20 (15%) transferred to another health care facility such as long-term acute care or a lower-acuity hospital.

In an exploratory analysis, we grouped centers according to geographical region within the United States and noted variation in hospital mortality (Figure E4). In compared with the Northeast, patients in the South incurred a numerically lower proportion of deaths (hazard ratio, 0.69; 95% CI, 0.43-1.04; *P* = .08) and those in the Midwest experienced significantly reduced mortality (hazard ratio, 0.43; 95% CI, 0.27-0.69; *P* < .01).

Clinical Factors Associated With In-Hospital Mortality

Multivariable adjustment analysis of baseline characteristics and laboratory variables revealed several factors related to in-hospital mortality. As shown in Figure 6, older age (adjusted hazard ratio [aHR], 1.26; 95% CI, 1.02-1.57 per 10 years), renal dysfunction measured according to serum creatinine level (aHR, 1.24; 95% CI, 1.01-1.53), and receiving cardiopulmonary resuscitation (CPR) before ECMO placement (aHR, 1.87; 95% CI, 1.01-3.46) were associated with death during hospitalization. Notably, sex, preexisting comorbidities, and length of intubation time before ECMO placement were not associated with death.

FIGURE 4. A comparison of the duration of hospitalization phases showing that extracorporeal membrane oxygenation (ECMO) was initiated earlier after admission in patients who were discharged/transferred alive compared with those who died. *IQR*, Interquartile range.

DISCUSSION

The principal findings of this, to our knowledge, largest to date US experience with ECMO use during COVID-19 are as follows: (1) death during hospitalization occurred in less than half of the patients, (2) patients discharged or transferred alive were given ECMO sooner after admission than those who died, (3) advancing age, renal injury,

FIGURE 5. The estimated cumulative incidence of in-hospital mortality after initiation of extracorporeal membrane oxygenation (ECMO) for COVID-19 at 90 days was 42% (95% confidence interval [CI], 36-47). The *solid line* shows the estimated cumulative incidence of in-hospital mortality and the *shaded region* represents the 95% CI.

and cardiopulmonary arrest requiring cardiopulmonary resuscitation during admission before ECMO placement forecasted reduced survival, (4) secondary infections occurred most of the patients, and (5) more than 80% of the patients discharged or transferred alive were either sent home or to a rehabilitation facility. Regional variation in hospital mortality is likely multifactorial and might be related to the initial burden of the pandemic in the United States, which was greatest in the Northeast. The lack of association between potential COVID-19 therapeutics and survival, in particular steroids, which have been shown to reduce mortality in hospitalized patients[17] could be related to the extreme severity of illness in patients who underwent ECMO support; however, the efficacy of such regimens cannot be determined using our registry-based study design and with concurrent administration of multiple therapies.

Our findings showed a similar cumulative incidence of in-hospital mortality at 90 days for patients with COVID-19 requiring ECMO compared with the worldwide experience in the ELSO registry, reported as 37%,[16] which persisted after exclusion of overlapping centers. Although both studies contain patients with a similar age distribution, burden of comorbidities, and levels of disease severity as evidenced by comparable PaO_2/FiO_2 ratios, small differences in outcome might be related to local unmeasured variations in patient selection and practices. Similar to the

	aHR, 95% CI, *P* value
Age (per 10 years)	**1.31 (1.06-1.61), .01**
Body Mass Index (per Kg/m2)	1.01 (0.98-1.04), .39
Male (vs. female)	0.87 (0.51-1.48), .61
Non-Hispanic Black (vs. Non-Hispanic White)	1.02 (0.51-2.04), .97
Hispanic (vs. Non-Hispanic White)	1.23 (0.73-2.08), .44
Other race / ethnicity (vs. Non-Hispanic White)	1.61 (0.74-3.52), .23
Pre-existing comorbidities	1.19 (0.74-1.90), .48
CPR prior to ECMO	**1.87 (1.01-3.46), .04**
Vasopressor Use	1.34 (0.84-2.15), .22
PaO2 to FiO2 ratio (per 1 mm Hg)	0.99 (0.99-1.00), .51
Serum Creatinine (per 1 mg/dL)	**1.21 (1.01-1.45), .04**
Lactate Dehydrogenase (highest tertile)	1.53 (0.85-2.78), .16
Lactate Dehydrogenase (middle tertile)	1.11 (0.62-1.97), .73
Time from intubation to ECMO	1.03 (0.98-1.07), .24
Intravenous steriod use	1.06 (0.62-1.83), .83

0.1   1   10
aHR

FIGURE 6. A multivariable Cox proportional hazards model of factors associated with in-hospital mortality in patients given extracorporeal membrane oxygenation (ECMO) for COVID-19. Older age, renal dysfunction, and cardiopulmonary resuscitation before ECMO placement were associated with in-hospital mortality. Preexisting comorbidities include hypertension and/or diabetes mellitus. Other race/ethnicity includes Asian, Pacific Islander, American Indian or other. *aHR,* Adjusted hazard ratio; *CI,* confidence interval; *CPR,* cardiopulmonary resuscitation; *PaO2,* partial pressure of oxygen; *FiO2,* fraction of inspired oxygen.

worldwide ELSO experience, we also noted that stroke occurred in 7% of the cases, with the bleeding subtype as most common, as is also apparent in non-COVID-19 patients.[5,18] As an external validation for the international ELSO study, this US-based experience provides corroborative evidence that ECMO support might lead to the survival for most patients afflicted by COVID-19-related ARDS.

Patients in our cohort met typical hypoxemia criteria during severe pneumonia and ARDS of a PaO2 to FiO2 ratio of <80 mm Hg despite standard ventilator management, which has been proposed as an indication for VV ECMO placement.[19] Upon comparing the clinical characteristics of our cohort with those from a large ECMO registry of non-COVID-19 patients (n = 2355), it is notable that patients included in our study were older (49 [IQR, 39-57] vs 41 [IQR, 28-34] years), but similar in proportion of cardiac arrest before ECMO (12% vs 9%) and had a higher PaO2 to FiO2 ratio (77 [IQR, 63-101] vs 59 [IQR 48-75]).[20] Few randomized trials have assessed the clinical utility of ECMO in patients with COVID-19. The Conventional ventilation or ECMO for Severe Adult Respiratory failure (CESAR) trial showed a reduction in death or severe disability at 60 days or before hospital discharge with ECMO (relative risk, 0.69; 95% CI, 0.05-0.97; *P* = .03).[21] More recently, the ECMO to Rescue Lung Injury in Severe ARDS (EOLIA) trial showed that 60-day mortality was 35% with immediate ECMO compared with 46% with continued conventional treatment (relative risk, 0.76; 95% CI, 0.55-1.04; *P* = .09).[22] Additional meta-analyses also show an improvement in survival with

ECMO for patients with severe and refractory respiratory failure.[23] Our cohort of patients with COVID-19 were similar to those in the EOLIA trial in age, PaO2/FiO2 ratio, and presence of comorbidities, thus providing a rationale to extrapolate that ECMO might indeed offer an effective treatment platform. However, such comparisons are limited because our patients received VV and VA ECMO and definitive measurements of efficacy can only be done in a randomized controlled trial.

Because nearly half of the patients did not survive to 90 days after ECMO placement, our findings do raise caution and point to judicious use of this treatment modality. To potentially optimize survival outcomes and manage expectations, we suggest that a treatment algorithm for patients with refractory respiratory failure from COVID-19 should take into consideration factors such as advanced age, renal failure, and pre-ECMO cardiopulmonary arrest when deciding whether to initiate ECMO. For patients with the preceding risk factors, consideration of comfort care measures might be appropriate as an alternative to ECMO, if consistent with their goals of care.

Survivors received ECMO sooner during admission than patients who expired. We speculate that this finding might relate to relatively more rapid restoration of oxygenation and limitation of irreversible end organ damage earlier during illness by ECMO placement. Thus, in appropriate candidates with refractory respiratory failure from COVID-19, early ECMO might potentially improve outcomes. Beyond survival, and in light of the elevated burden of adverse events including infection and renal replacement therapy

TABLE 3. Proposed areas of intervention and investigation for patients with COVID-19 requiring extracorporeal membrane oxygenation

Patient selection

- Risk score models to stratify prognosis at cannulation and during ECMO support. Advanced age, renal injury, and previous cardiopulmonary resuscitation would be considered in these models.
- Goals of care assessment
- Standardization of cannulation criteria

Circuit deployment

- Development and assessment of clinical pathways to closely monitor tenuous ventilated patients such as those with a PaO2/FiO2 ratio ≤100 for early ECMO within 48-72 h of presentation
- Determination of optimal anatomical cannulation sites
- Assessment of outcomes with cannulation through a RVAD-ECMO vs conventional ECMO configuration
- Comparison of differing hospital areas for ECMO cannulation

Patient management

- Optimal anticoagulation methods with comparison of differing pharmacotherapies
- Transfusion goals
- Effect of renal replacement therapy on outcomes
- Assessing benefit of attempting early extubation
- Appropriateness and timing of tracheostomy and comparison of percutaneous vs open technique
- Timing and thresholds of ECMO weaning for recovery or futility
- Evaluation of multidisciplinary teams for improving outcomes

Follow-up care

- Assessment of long-term functional outcomes

Network level

- Determination of prespecified maximal active case quotas and diversion strategies
- Establishment and assessment of networks for off-site cannulation
- Effect of center experience and specialization on outcomes and handling of incoming transfers

ECMO, Extracorporeal membrane oxygenation; *PaO2/FiO2*, partial presure of oxygen/fraction of inspired oxygen; *RVAD*, right ventricular assist device.

during ECMO support, it remains essential to determine the long-term functional and readmission outcomes of patients who were discharged or transferred alive. In our study, 54 (40%) and 20 (15%) of the patients who were discharged or transferred alive were sent to a rehabilitation facility or another health care facility, respectively. Further follow-up of these patients is warranted and will inform if ECMO is indeed an effective mode of therapy to reach meaningful recovery and quality of life.

Our study has several limitations. Because of the retrospective study design and lack of a non-ECMO control group, we cannot determine the efficacy of ECMO for patients with severe respiratory failure from COVID-19. In addition, a deeper characterization of the study cohort and outcomes is limited by lack of data availability for all collected variables. Outcomes from participating centers might not be reflective of those from institutions with lesser experience and different resource availability. There were no standardized criteria for patient selection or management among the participating centers. Because 15% of the patients were still hospitalized, the cumulative incidence of in-hospital mortality might change when these patients reach a final outcome. ARDS was not formally defined in our data collection tool. Notwithstanding the aforementioned limitations, we surmise that in light of the pandemic nature of COVID-19, our data provide important knowledge

that can meaningfully affect de novo and ongoing use of this resource-intensive therapy. We advocate for the development of a comprehensive and centralized prospective database to capture granular clinical information and show outcomes in real time. The database and network of centers formed through this collaborative analysis could serve as an expandable platform to address gaps in knowledge noted by our data and listed in Table 3 to pave the path toward improving outcomes.

In summary, our findings indicate that ECMO might serve as a useful method of advanced pulmonary support in patients with refractory respiratory failure from COVID-19. These data provide further credence for usage of ECMO in appropriate patients with severe COVID-19 and reinforce resource allocation toward this beneficial modality.

Conflict of Interest Statement

A.J.T and G.S are consultants for Abbott Laboratories outside of the submitted work. S.S is a consultant for Abbott Laboratories, Medtronic, Syncardia, and Abiomed outside o the submitted work. All other authors reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict

References

1. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region—case series. *N Engl J Med*. 2020;382:2012-22.

2. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA*. 2020;323:2052-9.

3. Potere N, Valeriani E, Candeloro M, Tana M, Porreca E, Abbate A, et al. Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. *Crit Care*. 2020;24:1-12.

4. Abrams D, Brodie D. Extracorporeal membrane oxygenation for adult respiratory failure: 2017 update. *Chest*. 2017;152:639-49.

5. Vaquer S, de Haro C, Peruga P, Oliva JC, Artigas A. Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome. *Ann Intensive Care*. 2017;7:51.

6. Jacobs JP, Stammers AH, Louis JS, Awori Hayanga JW, Firstenberg M, Mongero LB, et al. Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: experience with 32 patients. *ASAIO J*. 2020;66:722-30.

7. Sultan I, Habertheuer A, Usman AA, Kilic A, Gnall E, Friscia ME, et al. The role of extracorporeal life support for patients with COVID-19: Preliminary results from a statewide experience. *J Card Surg*. 2020;35:1410-3.

8. Henry BM, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): pooled analysis of early reports. *J Crit Care*. 2020;58:27-8.

9. Schmidt M, Hajage D, Lebreton G, Monsel A, Voiriot G, Levy D, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. *Lancet Respir Med*. 2020;8:1121-31.

10. Miike S, Sakamoto N, Washino T, Kosaka A, Kuwahara Y, Ishida T, et al. Critically ill patients with COVID-19 in Tokyo, Japan: a single-center case series. *J Infect Chemother*. 2020;27:291-5.

11. Mustafa AK, Alexander PJ, Joshi DJ, Tabachnick DR, Cross CA, Pappas PS, et al. Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure. *JAMA Surg*. 2020;155:990-2.

12. Bartlett RH, Ogino MT, Brodie D, McMullan DM, Lorusso R, MacLaren G, et al. Initial ELSO guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure. *ASAIO J*. 2020;66:472.

13. Ñamendys-Silva SA. ECMO for ARDS due to COVID-19. *Heart Lung*. 2020;49:348-9.

14. Satagopan J, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach A. A note on competing risks in survival data analysis. *Br J Cancer*. 2004;91:1229-35.

15. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat*. 1988;16:1141-54.

16. Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. *Lancet*. 2020;396:1071-8.

17. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med*. 2021;384:693-704.

18. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frato G, et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. *Crit Care Resusc*. 2013;15:172-8.

19. Brodie D, Slutsky AS, Combes A. Extracorporeal life support for adults with respiratory failure and related indications: a review. *JAMA*. 2019;322:557-68.

20. Schmidt M, Bailey M, Sheldrake J, Hodgson C, Aubron C, Rycus PT, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. *Am J Respir Crit Care Med*. 2014;189:1374-82.

21. Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet*. 2009;374:1351-63.

22. Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *N Engl J Med*. 2018;378:1965-75.

23. Munshi L, Walkey A, Goligher E, Pham T, Uleryk EM, Fan E. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. *Lancet Respir Med*. 2019;7:163-72.

Key Words: COVID-19, ECMO, ARDS, mortality

ADULT

	aHR, 95% CI, *P* value
Age (per 10 years)	1.35 (1.10-1.67), .001
Body Mass Index (per Kg/m2)	1.02 (0.99-1.05), .21
Male (vs. female)	0.79 (0.47-1.32), .38
Non-Hispanic Black (vs. Non-Hispanic White)	0.79 (0.47-1.32), .78
Hispanic (vs. Non-Hispanic White)	1.10 (0.55-2.21), .38
Other race / ethnicity (vs. Non-Hispanic White)	1.26 (0.75-2.12), .24
Hypertension	1.02 (0.61-1.72), .94
Diabetes Mellitus	0.67 (0.40-1.13), .13
CPR prior to ECMO	2.01 (1.07-3.76), .03
Vasopressor Use	1.38 (0.86-2.21), .19
PaO2 to FiO2 ratio (per 1 mm Hg)	1.00 (0.99-1.00), .60
Serum Creatinine (per 1 mg/dL)	1.20 (0.99-1.46), .06
Lactate Dehydrogense (higher tertile)	1.34 (0.75-2.41), .32
Lactate Dehydrogense (middle tertile)	0.98 (0.56-1.71), .94
Time from intubation to ECMO	1.02 (0.98-1.07), .27
Intravenous steriod use	1.04 (0.59-1.84), .90

0.1   1   10

aHR

FIGURE E1. A multivariable Cox proportional hazards model of factors associated with in-hospital mortality in patients given extracorporeal membrane oxygenation (ECMO) for COVID-19. Other race/ethnicity includes Asian, Pacific Islander, American Indian or other. Hypertension and diabetes mellitus are shown as separate covariates to distinguish from Figure 6, in which they are combined. *aHR*, Adjusted hazard ratio; *CI*, confidence interval; *CPR*, cardiopulmonary resuscitation; *PaO2*, partial pressure of oxygen; *FiO2*, fraction of inspired oxygen.

FIGURE E2. Estimated incidence of in-hospital mortality and usage of intravenous (IV) steroids (A) and remdesivir (B) after initiation of extracorporeal membrane oxygenation (ECMO) support for COVID-19 patients. Administration of IV steroids or remdesivir was not associated with in-hospital mortality.

**FIGURE E3.** The estimated cumulative incidence of in-hospital mortality after initiation of extracorporeal membrane oxygenation (ECMO) only in patients from centers not included in the Extracorporeal Life Support Organization report. In this subset of patients, the 90-day cumulative incidence of death in the hospital was 42% (95% confidence interval [CI], 35-49). The *solid line* shows the estimated cumulative incidence of in-hospital mortality and the *shaded region* represents the 95% CI.

**FIGURE E4.** A comparison of the estimated cumulative incidence of in-hospital mortality after initiation of extracorporeal membrane oxygenation (ECMO) for COVID-19 for centers from the Northeast, South, and Midwest regions of the United States showed variation in survival.

TABLE E1. List of collected variables in the REDCap database

Center ID
Covid 19 confirmed (Y/N)
Age
Sex
Weight, Kg
Body mass index
Race (drop box)
Ethnicity (drop box)
Preexisting conditions (drop box)
Other significant medical history
Date of symptoms onset
Date of presentation to hospital
Date of intubation
Time of intubation
Prone position prior to ECMO (Y/N)
Transferred (Y/N)
If transferred, date of transfer?
CPR before ECMO (Y/N)
Glasgow Coma Scale*
White blood cell count, $10^3/\mu L$
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Vasopressor use (Y/N)
Platelet count, $10^3/\mu L$
Serum creatinine, mg/dL
Serum total bilirubin, mg/dL
Ferritin, ng/mL
C-reactive protein, mg/dL
D-dimer, μg/mL
International normalized ratio
Fibrinogen, mg/dL
Lactate dehydrogenase, U/L
High-sensitivity troponin, ng/mL
Troponin I, ng/mL
Troponin T, ng/mL
pO2
FiO2
pH
P/F ratio (calculated)
pCO2
Lactic acid, mmol/L
Procalcitonin, ng/mL
Chloroquine (Y/N)
Hydroxychloroquine (Y/N)
Azithromycin (Y/N)

(Continued)

TABLE E1. Continued

IL-6 inhibitor (Y/N)
IL-1 inhibitor (Y/N)
CCR5 inhibitor (Y/N)
Intravenous steroids (Y/N)
Remdesivir (Y/N)
Lopinavir/ritonavir (Y/N)
Convalescent plasma (Y/N)
Intravenous heparin (Y/N)
Intravenous bivalirudin (Y/N)
Intravenous argatroban (Y/N)
Left ventricular ejection fraction, %*
Date of ECMO placement
Time of ECMO placement
Initial ECMO configuration (VV, VA, VAV)
Cannulation type (drop box)
Location of cannulation in the hospital (drop box)
Complications (Y/N)
Circuit exchange (Y/N)
Bleeding requiring transfusion (Y/N)
Renal failure requiring renal replacement therapy (Y/N)
Secondary infection (Y/N)
Which secondary infection (drop box)
Date of secondary infection
Deep vein thrombosis (Y/N), if yes then date of diagnosis
Hemorrhagic stroke during ECMO (Y/N), if yes then date of diagnosis
Ischemic stroke during ECMO, if yes then date of diagnosis
Change in ECMO configuration (drop box)
Continues receiving ECMO (Y/N)
Died during ECMO (Y/N), if yes, date of death
Cause of death (drop box)
Decannulated (Y/N), if yes, date of decannulation
Died after ECMO decannulation, if yes date of death
Discharged (Y/N), if yes date of discharge
90-Day outcome after ECMO placement (drop box)

Troponin was not reported due to variations in assay type. *REDCap*, Research Electronic Data Capture; *Y*, yes; *N*, no; *ECMO*, extracorporeal membrane oxygenation; *CPR*, cardiopulmonary resuscitation; *pO2*, partial pressure of oxygen; *FiO2*, fraction of inspired oxygen; *P/F*, partial pressure of oxygen to fraction of inspired oxygen ratio; *pCO2*, partial pressure of carbon dioxide; *IL*, interleukin; *CCR5*, C-C chemokine receptor type 5; *VV*, venovenous; *VA*, venoarterial; *VAV*, venoarterial venous. *Not reported since missing for >80% of cases.

TABLE E2. Univariable associations between baseline demographic characteristics, laboratory parameters, and in-hospital mortality

	Available observations	HR (95% CI)	P value
Age, y	292	1.03 (1.01-1.04)	<.01
Sex, n (%)			
Male sex (vs female sex)	292	0.85 (0.57-1.25)	.40
BMI	288	0.99 (0.97-1.01)	.43
Race/ethnicity, n (%)	285		
Non-Hispanic black (vs non-Hispanic white)		1.23 (0.67-2.23)	.51
Hispanic (vs non-Hispanic white)		1.11 (0.68-1.80)	.69
Other (vs non-Hispanic white)		1.42 (0.69-2.95)	.34
Preexisting comorbidities, n (%)	290	1.35 (0.91-1.99)	.14
Hypertension	292	1.11 (0.78-1.62)	.55
Diabetes mellitus	292	0.77 (0.51-1.16)	.21
COPD	292	0.54 (0.13-2.17)	.39
Malignant neoplasm	292	1.53 (0.31-7.51)	.41
Coronary artery disease	292	1.07 (0.45-2.57)	.87
Cardiopulmonary resuscitation, n (%)	292	1.66 (0.99-2.84)	.06
Transferred to ECMO hospital, n (%)	292	0.98 (0.68-1.42)	.93
Prone positioning, n (%)	287	1.28 (0.81-2.20)	.30
Time from symptom onset to admission, days	261	0.97 (0.92-1.02)	.19
Time from admission to intubation, days	279	1.04 (1.01-1.07)	.01
Time from intubation to ECMO, days	288	1.02 (0.99-1.06)	.21
Systolic blood pressure, mm Hg per 10 units	269	0.93 (0.85-1.02)	.13
Diastolic blood pressure, mm Hg per 10 units	269	0.93 (0.81-1.07)	.30
Vasopressors, %	275	1.71 (1.12-2.62)	.01
Blood gas parameters			
pH	279	0.42 (0.10-1.74)	.23
PaO2/FiO2, per 10 units	278	0.98 (0.95-1.02)	.33
PaCO2, mm Hg per 10 units	277	0.99 (0.95-1.04)	.81
Laboratory parameters			
White blood cells, $\times 10^3/\mu L$	278	1.01 (0.99-1.03)	.22
Platelet count, $\times 10^3/\mu L$ per 100 units	271	0.91 (0.78-1.07)	.25
Lactic acid, mmol/L	256	0.98 (0.95-1.02)	.40
Creatinine, mg/dL	278	1.03 (1.00-1.06)	.02
INR	237	1.00 (0.86-1.16)	.96
Total bilirubin, mg/dL	266	1.02 (0.80-1.30)	.22
Ferritin, ng/mL per 100 units	233	1.00 (0.99-1.01)	.96
C-reactive protein, mg/dL per 10 units	210	1.01 (1.00-1.01)	.02
D-dimer, μg/mL	261	1.00 (0.99-1.00)	.80
Fibrinogen, mg/dL per 100 units	162	0.96 (0.88-1.04)	.27
Lactate dehydrogenase, U/L per 100 units	241	1.02 (1.05-1.03)	<.01
Highest tertile	80	1.25 (0.76-2.04)	.37*
Middle tertile	80	0.99 (0.60-1.63)	.96*
Lowest tertile	81		
Missing	51		
Procalcitonin, ng/mL	217	1.03 (0.98-1.03)	.82

HR, Hazard ratio; *CI,* confidence interval; *BMI,* body mass index; *COPD,* chronic obstructive pulmonary disease; *ECMO,* extracorporeal membrane oxygenation; *PaO2/FiO2,* partial pressure of oxygen/fraction of inspired oxygen; *PaCO2,* partial pressure of carbon dioxide; *INR,* international normalized ratio. *Compared with lowest tertile.

TABLE E3. Usage of potential COVID-19 therapeutics and univariate association with in-hospital mortality

	All patients (N = 292)	Still receiving ECMO (n = 19)	No ECMO but remain hospitalized (n = 25)	Discharged/ transferred alive (n = 135)	Died (n = 113)	Available observations	HR (95% CI)	P value
Chloroquine	3 (1)	0 (0)	0 (0)	1 (1)	2 (2)	277	3.49 (0.50-24.39)	.21
Hydroxychloroquine	137 (49)	7 (37)	11 (46)	75 (56)	44 (44)	277	0.79 (0.52-1.14)	.19
Azithromycin	182 (64)	10 (56)	17 (68)	94 (70)	61 (57)	284	0.73 (0.50-1.06)	.10
Interleukin 1 inhibitor	12 (4)	0 (0)	1 (4)	5 (4)	6 (6)	272	1.57 (0.66-3.76)	.31
Interleukin 6 inhibitor	171 (61)	13 (72)	15 (63)	81 (60)	62 (59)	281	0.89 (0.61-1.31)	.56
CCR5 inhibitor	4 (2)	0 (0)	0 (0)	3 (2)	1 (1)	273	0.61 (0.13-3.02)	.55
Intravenous steroids	216 (75)	16 (84)	19 (76)	97 (72)	84 (78)	287	1.07 (0.67-1.72)	.78
Remdesivir	115 (41)	10 (53)	10 (42)	46 (35)	49 (47)	278	1.36 (0.93-1.99)	.11
Lopinavir/ritonavir	6 (2)	0 (0)	0 (0)	3 (2)	3 (3)	273	1.49 (0.48-4.66)	.49
Convalescent plasma	122 (43)	10 (53)	8 (32)	50 (37)	54 (50)	285	1.43 (0.98-2.07)	.07

Data are presented as n (%); percentages represent the proportion of reported observations. *ECMO*, Extracorporeal membrane oxygenation; *HR*, hazard ratio; *CI*, confidence interval; *CCR5*, C-C chemokine receptor type 5.

ADULT